A recent study from Harvard University has unveiled intriguing findings about the social and economic effects of GLP-1 medications, commonly used for weight loss, on women. The research, led by Professor Rebecca Diamond, compared women who began using GLP-1s with those who aspired to start the treatment but had yet to do so. The study, published by the National Bureau of Economic Research, suggests that these medications may significantly influence women’s job prospects and relationship statuses.
:max_bytes(150000):strip_icc():format(jpeg)/smaglutide-injection-010826-2dee247cb85f4208b7d58ccc1400051d.jpg)
Professor Diamond’s interest in this area was sparked by a conversation with a friend who noted a notable change in how people treated her after she lost weight using GLP-1 medications. This prompted Diamond to investigate whether there was any academic literature exploring the broader economic and social implications of GLP-1 usage. After conducting a quick review, she found a gap in existing research, prompting deeper inquiry into the matter.
The study utilised data from the Understanding America Study, a comprehensive Internet panel comprising around 15,000 residents across the United States, managed by the University of Southern California. Through her analysis, Diamond specifically compared two groups of women: those who had commenced treatment with GLP-1s for weight reduction and those who had expressed a desire to begin treatment but had not yet done so.
The findings from the analysis were striking. For women who were single when they started taking GLP-1, the likelihood of subsequently entering into marriage or cohabitation significantly increased. Specifically, the probability of finding a partner rose by 18 percentage points after beginning treatment and expanded to an impressive 29 percentage points after six or more quarters of usage. This indicates a strong correlation between weight loss medication and enhanced prospects in romantic relationships.
Moreover, the research highlighted a positive trend concerning employment. Women who were unemployed at the start of their GLP-1 regimen saw a notable uplift in their likelihood of finding a job. Overall, the employment rate for this group increased by 13 percentage points, climbing to 27 percentage points over a longer horizon of six quarters. Additionally, the weekly hours worked by these women grew by nearly ten hours during the same time frame. Importantly, most of this employment rise stemmed from a shift out of unemployment rather than transitions from other permanent states such as retirement or disability.
An interesting aspect to emerge from Diamond’s research was the stability of job and relationship metrics for women who were already employed or in partnerships when they began taking GLP-1s. The study revealed that there was no significant change in these women’s employment or relationship statuses, leading Diamond to conclude that their experiences of first impressions had likely already been established prior to beginning treatment.
Diamond elaborated on this observation, suggesting that motivation stemming from the commencement of a new medication might not drive changes in existing job performance or relationship dynamics. “For those who have been in a job for a long time, employers likely already have a sense of their capabilities and are not focused on weight as a factor anymore,” she explained. Similarly, in established relationships, partners typically value more than just physical appearance — a sentiment that may reduce the impact of weight loss on pre-existing partnerships.
In light of these findings, there are broader implications for how society perceives women who use GLP-1 medications. As the study indicates, the initial societal perception may shift with weight loss, resulting in enhanced opportunities in both professional and personal domains. However, the effects seem to differ based on the timing of weight loss in relation to existing social and economic commitments.
As the conversation around weight management continues, findings like those presented by Diamond could challenge existing perceptions surrounding GLP-1 drugs, showcasing their potential as transformative agents in women’s lives beyond mere weight loss. With growing interest in the implications of these medications, this research could pave the way for further studies exploring the extensive social and economic influences of weight-loss treatment options on diverse demographics.
Women contemplating the use of GLP-1 medications may find solace in these findings, particularly those seeking new professional or relationship avenues. However, it remains critical for ongoing research to take into account the complexities surrounding body image, societal expectations, and personal well-being, ensuring that every woman’s journey is viewed through a lens that appreciates the multifaceted nature of weight loss and its myriad effects on life.